Dr Pies is Professor Emeritus of Psychiatry and Lecturer on Bioethics and Humanities, SUNY Upstate Medical University; Clinical Professor of Psychiatry, Tufts University School of Medicine; and Editor in Chief Emeritus of Psychiatric Times (2007-2010). Dr Pies is the author of several books. A collection of his works can be found on Amazon.
I do not hear loud applause for our current antidepressant armamentarium. I believe I hear the sound of one hand clapping.
Two hands clap and there is a sound. What is the sound of one hand?
-Hakuin Ekaku (Rinzai Zen Master, 1686-1768)
From my perspective, we are witnessing what might be called a crisis of faith in the realm of antidepressant treatment. Now, “faith” is a curious term. It may imply something like “confidence”-or something more akin to “deep religious conviction.” My experience with a few recent blog postings has convinced me that both interpretations apply to the state of antidepressant research and treatment.
First, there is the issue of confidence, with respect to the efficacy of antidepressants (ADs) in both acute treatment studies and studies of long-term prophylaxis. (“Efficacy” usually refers to benefit under controlled, clinical conditions; “effectiveness,” to naturalistic settings). It turns out that the reported efficacy of ADs in acute treatment studies is, to a large degree, in the eye of the beholder-or of the statistical analyst. A great deal depends, for example, on how much stock we put in a 2- or 3-point change on the Hamilton Depression Rating Scale (HDRS, commonly known as the HAM-D) and how we understand the nature of the “placebo response.”
Nearly all acute efficacy studies of ADs make use of the HAM-D, which is actually subject to a variety of confounds, such as the training of the HAM-D raters.1 And, depending on whether one considers a mean change of 2 or 3 points on the HAM-D to be clinically significant, meta-analyses of acute AD efficacy studies lead to different conclusions. Furthermore, placebo responses have been rising in recent years because of a variety of factors, such as multisite studies and use of less severely depressed patients.2 It is hard to apply the results of randomized, placebo-controlled studies to clinical practice. Thus, in a superb review, Prof Hans-Jrgen Mller3 concludes:
“In interpreting such mean [HAM-D] score differences, it has to be stated that the mean of the pre-post differences of the placebo groups and the verum [active medication] groups only give a global estimation of efficacy under the artificial conditions of placebo-controlled trials, in which, due to the principal characteristics of the design, the verum response is underestimated and the placebo response is overvalued. . . . One cannot conclude very much from this for everyday clinical practice, especially not on the efficacy for special patient subgroups or even for individual patients.”
Furthermore, as an extensive critique of the much-discussed Kirsch4 meta-analysis pointed out,
“Perhaps the most overlooked aspect of the data included in Kirsch et al. (2008) is that it is not about the effects of antidepressants upon depression, but rather about the effects of antidepressants on the HAMD . . . [and the HAM-D] describes a construct of depression which corresponds poorly to that found in DSM-IV . . .[underline added]”5
Having recently reviewed the extensive antidepressant literature for a paper in press,6 my own conclusion is that ADs show, overall, modest-to-moderate efficacy compared with the placebo condition in acute treatment studies-depending on the type and severity of depression. I use the term “placebo condition” advisedly, since inclusion in this condition involves far more than popping a “sugar pill” into the patient’s mouth, as the lay press likes to imagine. Dr. Sheldon Preskorn7 has noted that in a typical randomized placebo-controlled trial, subjects in the placebo condition often receive 8 to 12 hours of supportive and educative care-more than many depressed patients in “the real world” receive from their doctors! We simply don’t know how this supportive component may modify the “intrinsic” properties of a placebo tablet-but my guess is, there is considerable synergism.
The most robust AD effects in acute treatment studies seem to emerge in more severely depressed patients (although there is controversy on this point) and among those with melancholic features.8 However, a recent re-analysis of the Kirsch data by Ghaemi and Vhringer9 found acute antidepressant efficacy in both moderate and severe-but not in mild-major depression. This should not really surprise us. All other factors being equal, the farther we move down the continuum from severe melancholic major depression toward normal sadness, the less pronounced the difference between specific and nonspecific interventions (like the placebo condition). In partial contrast, long-term maintenance studies of ADs seem to show a more robust drug-placebo difference. As Mller3 notes:
“If the results of placebo-controlled studies regarding a maintenance therapy with antidepressants (maintenance of the response for 6-12 months after the acute therapy) are considered . . . the conclusion regarding the clinical relevance of antidepressants is even strengthened. Geddes et al (Geddes et al. 2003) in their meta-analysis of 31 randomized, double-blind, placebo-controlled studies found a highly significant efficacy of continuation therapy, with relapse rates of 41% under placebo versus 18% under verum [active medication] . . .”
To be sure, there are methodological issues that arise with many long-term studies; eg, the use of “enriched” samples (known responders to the medication) during the maintenance phase, which tends to bias outcomes in favor of the active drug.9 Furthermore, several researchers have questioned whether most “maintenance” studies are demonstrating true prophylaxis, or mere “relapse prevention.”10 Arguably, one would need to see prevention of depressive recurrence 6 months or more after the index depressive episode in order to show a true prophylactic effect. Nevertheless, reducing the risk of relapse in severe major depression, even for 6 months, is not a trivial benefit in a potentially lethal disorder.
While I endorse the randomized, double-blind, placebo-controlled trial (RCT) as the “gold standard” of scientific research, we also need more naturalistic, “real-world” studies of antidepressants. After all, most RCTs select “depressed” patients the likes of whom most of us rarely see: patients without active suicidal intentions, substance abuse, or comorbid conditions on Axes II and III, many of whom are recruited from nonclinical settings.
One encouraging “real-world” study comes from Leon et al,11 who carried out a 27-year observational study of antidepressants.11 The authors concluded that “. . . antidepressants were associated with a significant reduction in the risk of suicidal behavior,” which was defined as a reduction in actual suicide attempts or completed suicides while taking ADs. This is consistent with most epidemiological studies and shows an association between AD prescription and stable or declining suicide rates.12 If the Leon et al findings are confirmed, we will have convincing evidence that ADs are providing a substantial benefit to depressed patients, in “real-world” conditions.
The other dimension in this crisis of faith involves the more religious connotation I alluded to earlier-and here we must depart the realm of “pure science.” It is clear to me that among the general public, there is a vociferous and sometimes vitriolic group who fervently and inflexibly believe that antidepressants are worse than useless-indeed, who see these medications as quite toxic and dangerous. My sense is that many of these individuals fit the description of the “true believer,” as described by philosopher Eric Hoffer13(p76):
“It is the true believer’s ability to “shut his eyes and stop his ears” to facts that do not deserve to be either seen or heard which is the source of his unequaled fortitude and constancy.”
(Of course, characteristically, these opponents of antidepressants view psychiatrists as having precisely the same blinkered obstinacy.) Hoffer13(p86) goes on to say that
“Mass movements can rise and spread without belief in a God, but never without belief in a devil. Usually the strength of a mass movement is proportionate to the vividness and tangibility of its devil.”
Indeed, this loosely knit community of naysayers sees psychiatry and psychiatrists in nearly satanic terms. For them, however, the “devil” is a Chimera-like creature, with the head of a fraudulent researcher; the body of a drug sales rep; and the tail of a psychiatrist. I do not intend to publicize the Web sites of these individuals, but you can read some of their comments by linking to the blog sites below.*13,14
Now, it is tempting to write these individuals off as fear-mongering cranks, possessed of only the faintest scientific knowledge. A handful certainly fit that description-the ones, for example, who insist that antidepressants are destroying the brains of millions; causing thousands of suicides; and turning scores of once-placid accountants into knife-wielding, psychotic killers. Oh, yes-and causing permanent sexual dysfunction in thousands of patients. (The actual prevalence of this last phenomenon is not known, though, to my knowledge, there are fewer than 30 such cases in the published literature-see references 15 and 16.) These individuals will probably never be persuaded, no matter the evidence, that antidepressants are usually effective and well-tolerated when properly prescribed and monitored.
And yet, dismissing all critics of psychiatric treatment as querulous crackpots would be a serious mistake. Some of those who wrote to me were both knowledgeable about psychiatric medications, and sophisticated in their grasp of medical research. Some spoke from painful personal experience with psychiatric medications-whether antidepressants, antipsychotics, or mood stabilizers. They spoke, for example, of becoming agitated or manic while taking antidepressants, and feeling depressed or “doped up” while taking mood stabilizers. They spoke of painful “withdrawal symptoms” lasting many months, after their antidepressant was stopped. They spoke of lethargy, blunted creativity, or impaired cognition while taking antidepressants or mood stabilizers. Perhaps most disheartening, they spoke of how little they felt understood, “listened to,” or respected by their physicians.
It is of small consolation to these sincere critics when I reply, as I usually do, along the following lines:
“Well, yes: when antidepressants are prescribed by the wrong doctor to the wrong patient, and for the wrong reason, serious problems can occur. Patients with bipolar disorder may indeed become irritable, aggressive, or manic, and in general, should rarely be treated with antidepressants.17 And, yes: when patients are not carefully monitored, they can become excessively sedated, just as they may experience prolonged sexual dysfunction that is not detected by the prescribing physician-who is very likely not a psychiatrist.
“And, it is true that when a physician discontinues an antidepressant too rapidly, the patient may experience a very uncomfortable, flu-like syndrome that may last for days or weeks-rarely longer-which can nearly always be avoided by using a very slow tapering schedule, over several months. These are problems mainly related to poor medical practice, and only partly related to the properties of the medications themselves. These are problems that arise, in part, from inequities in our health care system, and the lack of affordable and accessible psychiatric care in this country.”
I don’t blame disgruntled patients for finding this apologia unconvincing, if not downright insensitive. When you have been made miserable by an inappropriate or poorly monitored medication, you are not likely to be mollified by the explanations of those prescribing-and not ingesting!-the drug in question. Ironically, given the complaints of these critics, the growing popularity of antidepressants in the United States18 does not suggest that physicians are getting a strong “Cease and desist!” signal from the vast majority of patients. On the contrary: the evidence suggests that most patients are generally satisfied with their antidepressant treatment. For example, a recent study by pharmacists found that among monitored patients taking antidepressants,
“Fifty-seven percent of patients reported feeling better a lot of the time, and an additional 30% reported feeling better some of the time. Nearly 75% reported that the antidepressant did not bother them or only bothered them a little of the time. Being very satisfied was reported by 47% of patients, and an additional 28% were satisfied with the antidepressant.”19
There is also encouraging news on the level of molecular biology. Antidepressants do not merely rev up levels of neurotransmitters, along the lines of the now outdated “chemical imbalance” hypothesis.14 Rather, ADs may work at the level of the gene, by promoting production of various neurotrophic peptides, such as brain-derived neurotrophic factor (BDNF). These factors, in turn, may enhance neuronal growth and survival, and appear to underlie the mechanism of several antidepressants.20
Rather than damaging the brain, ADs may actually work to enhance “neuroplasticity,” improve stress tolerance, and facilitate learning.21 That said, there are some concerns that in a small subset of patients who are treated long-term with ADs, a syndrome of “tardive dysphoria” may develop. Such a delayed, “pro-depressant” effect might reflect some as yet poorly understood “rebound” phenomenon in the brain.22 Clearly, we need more research on this troubling possibility.
Nonetheless-and contrary to the claims of critics-there is some evidence that patients treated with ADs report improvements in “quality of life” (QOL) and overall satisfaction with their lives. For example, a Belgian study of depressed or anxious patients taking the AD escitalopram found that treatment resulted in a significant improvement in quality of life enjoyment and satisfaction.23 However, we need many more studies examining QOL in patients taking antidepressants. HAM-D scores alone do not tell us whether a depressed patient has moved beyond mere remission to a full and flourishing recovery.
And so, overall, what is my verdict on antidepressants? In my estimation, our present medications for depression are only mediocre. For moderate to severe, and especially melancholic, cases of major depression, ADs are effective and sometimes lifesaving, particularly when part of a comprehensive treatment plan that includes psychotherapy. And, there is convincing evidence that ADs prevent relapse at least during the 6 months or so after a bout of major depression. For mild, non-melancholic cases of depression, I generally favor beginning with psychotherapy, given the “costs” of antidepressant side effects. In this regard, we urgently need to find antidepressants that are more effective and better tolerated. Recent research suggests that agents that modulate the N-methyl-D-aspartate (NMDA) system (eg, ketamine) are worth further exploration.24 In sum: I do not hear loud applause for our current antidepressant armamentarium. I believe I hear the sound of one hand clapping.
So what is next? We need to improve access to psychiatric care, so that patients who need antidepressants are seen by those best trained and most knowledgeable in their use. We need to work more closely with our colleagues in primary care, so that they become more proficient in the diagnosis and treatment of depression. We need to investigate carefully even the very rare side effects of antidepressants, so that we do not lose the confidence of the general public. We need to avoid even the appearance of conflicts of interest, related to “Big Pharma.” And perhaps most important, we need to listen attentively and respectfully when our patients tell us they are not happy with their treatment.
Acknowledgment-Thanks to James Knoll, MD, for his reading of an earlier draft of this paper. Thanks also to Nassir Ghaemi, MD, for providing me with insights into the Kirsch4 data.
*You will also bring up most of the relevant Web sites by entering the search terms “SSRI iatrogenic violence suicide stories seroxat” into a search engine.
References1. Kobak KA, Kane JM, Thase ME, Nierenberg AA. Why do clinical trials fail? The problem of measurement error in clinical trials: time to test new paradigms? J Clin Psychopharmacol. 2007;27:1-5.
2. Bridge JA, Birmaher B, Iyengar S, et al Placebo response in randomized controlled trials of antidepressants for pediatric major depressive disorder.Am J Psychiatry. 2009;166:42-49.
3. Moller H-J. Is the efficacy of antidepressants clinically relevant? CINP Perspectives Tuesday, September 13, 2011. http://cinp.org/cinp-perspectives/perspectives/?tx_mmforum_pi1[action]=list_post&tx_mmforum_pi1[tid]=9. Accessed October 10, 2011.
4. Kirsch I. Antidepressant drugs ‘work,’ but they are not clinically effective. Br J Hosp Med (Lond). 2008;69:359.
5. Horder J, Matthews P, Waldmann R. Placebo, Prozac and PLoS: significant lessons for psychopharmacology. J Psychopharmacol 2010 Jun 22; [Epub ahead of print]. doi:10.1177/0269881110372544.
6. Pies R. Are antidepressants effective in the acute and long-term treatment of depression? Sic et Non Innov Clin Neurosci. In press.
7. Preskorn S. A dangerous idea. J Pract Psychiatry Behav Health. 1996;2:231-234.
8. Brown WA. Treatment response in melancholia. Acta Psychiatr Scand Suppl. 2007;433:125-129
9. Ghaemi SN, VÃ¶hringer PA. Solving the antidepressant efficacy question? Effect sizes in major depressive disorder. Clin Therapeut. In press.
10. Goodwin FK, Whitham EA, Ghaemi SN. Maintenance treatment study designs in bipolar disorder: do they demonstrate that atypical neuroleptics (antipsychotics) are mood stabilizers? CNS Drugs. 2011;25:819-827.
11. Leon AC, Solomon DA, Li C, et al. Antidepressants and risks of suicide and suicide attempts: a 27-year observational study. J Clin Psychiatry. 2011;72:580-586.
12. Kalmar S. Correlation of suicide and antidepressant prescriptions (N06A) by gender and age groups in Hungary and BÃ¡cs-Kiskun County between 1999-2006 [in Hungarian]. Neuropsychopharmacol Hung. 2011;13:59-72.
13. Borchard TJ, Pies R. Are the Puritans behind the war on antidepressants? http://psychcentral.com/blog/archives/2011/09/13/are-the-puritans-behind-the-war-on-antidepressants/. Accessed October 10, 2011.
14. Pies R. Doctor, is my mood disorder due to a chemical imbalance? http://psychcentral.com/blog/archives/2011/08/04/doctor-is-my-mood-disorder-due-to-a-chemical-imbalance/. Accessed October 10, 2011.
15. Kauffman RP. Persistent sexual side effects after discontinuation of psychotropic medications. Prim Psychiatry. 2008;15:24. http://www.primarypsychiatry.com/aspx/articledetail.aspx?articleid=1479. Accessed October 10, 2011.
16.Csoka AB, Bahrick A, Mehtonen OP. Persistent sexual dysfunction after discontinuation of selective serotonin reuptake inhibitors. J Sex Med. 2008;5:227-233.
17. Strejilevich SA, Martino DJ, Marengo E, et al. Long-term worsening of bipolar disorder related with frequency of antidepressant exposure. Ann Clin Psychiatry. 2011;23:186-192.
18. Mojtabai R, Olfson M. Proportion of antidepressants prescribed without a psychiatric diagnosis is growing. Health Aff (Millwood). 2011;30:1434-1442.
19. Bultman DC, Svarstad BL. Effects of pharmacist monitoring on patient satisfaction with antidepressant medication therapy. J Am Pharm Assoc. 2002;42:36-43.
20.DreimÃ¼ller N, Schlicht KF, Wagner S, et al. Early reactions of brain-derived neurotrophic factor in plasma (pBDNF) and outcome to acute antidepressant treatment in patients with Major Depression. Neuropharmacology. 2011 Jul 22; [Epub ahead of print].
21.Andrade C, Rao NS. How antidepressant drugs act: a primer on neuroplasticity as the eventual mediator of antidepressant efficacy. Indian J Psychiatry. 2010;52:378-386.
22.El-Mallakh RS, Gao Y, Jeannie Roberts R. Tardive dysphoria: the role of long term antidepressant use in inducing chronic depression. Med Hypotheses. 2011;76:769-773.
23. Demyttenaere K, Andersen HF, Reines EH. Impact of escitalopram treatment on Quality of Life Enjoyment and Satisfaction Questionnaire scores in major depressive disorder and generalized anxiety disorder. Int Clin Psychopharmacol. 2008;23:276-286.
24. Li N, Lee B, Liu RJ, et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science. 2010;329:959-964.